Journals / Ulusal Cerrahi Dergisi / 2008 / Cilt: 24 - Sayı: 4

Response to neoadjuvant chemoradiation in locally advanced rectal cancer: Dokuz Eylül University experience

Lokal ileri rektum kanserinde neoadjuvan kemoradyoterapiye yanıt: Dokuz Eylül Üniversitesi deneyimi

Pages
193–199
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Surgical resection is still the primary treatment of resectable rectal cancer.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: The aim of this study was to evaluate the response to neoadjuvant long course chemoradiotherapy (CRT) for patients with locally advanced rectal cancer with or without lymph node metastasis.
📊
Key Findings & Data:Materials and Methods: Between 1993 – 2007, 126 patients with locally advanced rectal cancer with or without lymph node involvement were treated at Dokuz Eylul University Medical Faculty Hospital.
💡
Conclusion & Impact:Surgical resection is still the primary treatment of resectable rectal cancer.
🔬Design:Research Article
📍Scope:2007 Verileri
⚙️Variables:Rektum neoplazmları · Neoadjuvant tedavi · Neoplazm evrelendirilmesi

Abstract

Purpose: The aim of this study was to evaluate the response to neoadjuvant long course chemoradiotherapy (CRT) for patients with locally advanced rectal cancer with or without lymph node metastasis. Materials and Methods: Between 1993 – 2007, 126 patients with locally advanced rectal cancer with or without lymph node involvement were treated at Dokuz Eylul University Medical Faculty Hospital. Prospectively collected data of patients were analyzed. All patients received concurrent CRT. Curative intend surgical resection was performed 4 to 8 weeks after the completion of CRT. Response to neoadjuvant CRT was assessed by comparing the preoperative clinical staging and postoperative pathological evaluation. Histopathological complete response (pCR) was defined as no tumor cells within the specimen. Downstaging of T and/or N stage of the tumor was defined as partial response (PR). Results: Mean age was 57.9 years and 40,5% of patients were female, 59,5% of patients were male. Preoperative staging revealed T3 tumor in 54 (42,8%) of patients and T4 tumor in 58 (46%) of patients. In 32 (25,4%) patients there were no lymph node metastases (cN0) whereas in 94 (74,6%) patients lymph node involvement was detected (cN+). Tumor was located at lower rectum in 61,1% of patients, at mid-rectum in 25,4% of patients, and at upper rectum in 13,5% of patients. Sphincter saving resection was performed in 62,7% of patients. Histopathological complete response was observed in 13 (10,3%) patients. T stage downstaging was observed in 63 (%63) patients, N stage downstaging was observed in 57 (45,2%) patients, and PR was observed in 76 (60,3%) patients. No significant difference was observed between the response to neoadjuvant CRT and tumor localization and sphincter saving resection (P>0.05). Conclusion: Response to neoadjuvant CRT was obtained in majority of the patients. Downstaging was not associated with the rate of sphincter preserving surgery. Surgical resection is still the primary treatment of resectable rectal cancer.

Özet

Amaç: Lokal ileri ve/veya lenf düğümü tutulumu olan rektum kanseri nedeniyle uzun dönem neoadjuvan kemoradyoterapi (KRT) uygulanan hastalarda tümörün T ve N evresinde gerileme ve patolojik tam yanıt oranlarının belirlenmesi amaçlanmıştır. Gereç ve Yöntem: Dokuz Eylül Üniversitesi Tıp Fakültesi Hastanesinde 1993 – 2007 yıllarında tedavisi yapılmış lokal ileri (T3/T4) ya da lenf düğümü tutulumu olan (evre II-III) 126 rektum kanserli hastanın prospektif olarak toplanmış verileri değerlendirildi. Tüm hastalara eşzamanlı KRT uygulandı. Küratif amaçlı cerrahi rezeksiyon KRT bitiminden 4-8 hafta sonra yapıldı. Neoadjuvan KRT'ye yanıtın değerlendirmesi ameliyat öncesi evreleme ile patolojik evrenin karşılaştırılması ile yapıldı. Rezeksiyon materyalinde herhangi bir kanser hücresi gözlenmemesi (ypT0N0), patolojik tam yanıt (pTY) olarak değerlendirildi. Tümörün T ve N evresindeki gerileme (TG ve NG) kısmi yanıt (KY) olarak değerlendirildi. Bulgular: Serideki hastaların ortalama yaşı 57,9 idi. Olguların %40,5'i kadın, %59,5'i erkek idi. Tedavi öncesi yapılan radyolojik incelemelerde olguların 54 (%42,8)'ünde T3, 58 (%46)'inde T4 tümör saptandı; olguların 32 (%25,4)'sinde lenf düğümü metastazı izlenmezken (cN0), 94 olguda (%74,6) lenf düğümü metastazı saptandı (cN+). Tümörün yerleşim yeri olguların %61,1'inde alt rektum, %25,4'ünde orta rektum, %13,5'inde üst rektum idi. Sfinkter koruyucu cerrahi olguların %62,7'sinde uygulanabildi. Neoadjuvan KRT sonrası pTY (ypT0N0) olguların 13 (%10,3)'ünde izlendi. Serideki 63 (%63) olguda TG, 57 (%45,2) NG, 76 (%60,3) olguda KY izlendi. Neoadjuvan tedaviye yanıt ile tümör yerleşimi ve sfinkter koruyucu cerrahi uygulanabilirliği arasında istatistiksel olarak anlamlı farklılık izlenmemiştir (P>0.05). Sonuç: Neoadjuvan KRT uygulanan hastaların büyük bir kısmında tümörde boyut ve/veya evre gerilemesi sağlanabilmektedir. Evre gerilemesi, sfinkter koruyucu cerrahi uygulanabilirliğini arttırmamaktadır. Rezeke edilebilir rektum kanserlerinin primer tedavisi cerrahidi

🔖

Cite This Article

CANDA, A. E., TERZİ, C., SARIOĞLU, S., GÖRKEN, İ. B., ALANYALI, H., OBUZ, F., YILMAZ, U., ÖZTÜP, İ., SÖKMEN, S., FÜZÜN, M. (2008). Response to neoadjuvant chemoradiation in locally advanced rectal cancer: Dokuz Eylül University experience. Ulusal Cerrahi Dergisi, Cilt: 24 - Sayı: 4, 193–199. https://ajindex.com/articles/325597

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Chen ET, Mohiuddin M, Brodovsky H, Fishbein G, Marks G. Downstaging of advanced rectal cancer following combined preoperative chemotherapy and high dose radiation. Int J Radiat Oncol Biol Phys 1994; 30: 169–175
  2. Minsky BD, Cohan AM, Enker WE, Paty P. Sphincter preservation with preoperative radiation therapy and coloanal anastomosis. Int J Radiat Oncol Biol Phys 1995; 31: 553–559
  3. Rouanet P, Fabre JM, Dubois JB, et al. Conservative surgery for low rectal carcinoma and high-dose radiation: functional and oncological results. Ann Surg 1995; 221: 67–73
  4. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-1740
  5. Buroker T, Nigro N, Correa J, Vaitkevicius VK, Samson M, Considine B. Combination preoperative radiation and chemotherapy in adenocarcinoma of the rectum: preliminary report. Dis Colon Rectum 1976;19: 660–663
  6. Minsky BD, Cohen AM, Kemeny N, et al. Efficacy of preoperative 5-FU, high dose leucoverin, and sequential radiation therapy for unresectable rectal cancer. Cancer 1994; 73: 273–280
  7. Wheeler JM, Dodds E, Warren BF, et al. Preoperative chemoradiotherapy and total mesorectal excision surgery for locally advanced rectal cancer: correlation with rectal cancer regression grade. Dis Colon Rectum 2004; 47: 2025-2031
  8. Quirke P, Durdey P, Dixon MF, Williams NS. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. Lancet 1986; 2: 996-999
  9. Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1986; 1: 1479-1482
  10. Halefoglu AM, Yildirim S, Avlanmis O, Sakiz D, Baykan A. Endorectal ultrasonography versus phased-array magnetic resonance imaging for preoperative staging of rectal cancer. World J Gastroenterol 2008; 14: 3504-3510
  11. Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997; 336: 980-987
  12. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345: 638-646. 12)
  13. Bosset JF, Collette L, Calais G, et al; EORTC Radiotherapy Group Trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355: 1114-1123
  14. Gérard JP, Conroy T, Bonnetain